Automation
IT & Software

IT & Software News

View news from other Pharmaceutical sectors:
31-45 of 1781 results
Ligand Pharmaceuticals signs OmniAb license deal with TeneoBio
Ligand Pharmaceuticals has entered into a worldwide license agreement with Menlo Park, CA-based TeneoBio.
Automation > IT & Software > News
Xencor starts phase 1b trial of subcutaneous formulation of XmAb7195
Xencor has dosed the first patient in a Phase 1b multi-dose trial of subcutaneously administered XmAb7195, a potential treatment for allergic disease.
Automation > IT & Software > News
Pfizer launches app to help patients manage depression
Pfizer has launched a new app, Moodivator, to help motivate and encourage the millions of adults who experience depression.
Automation > IT & Software > News
Xencor doses first patient in phase 1 clinical trial of XmAb14045
Xencor has dosed the first patient in a Phase 1 clinical trial of XmAb14045 for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies.
Automation > IT & Software > News
EPAM, Sinequa partner to address cognitive search & analytics challenges in pharma industry
EPAM Systems and Sinequa have partnered to deliver search and analytics solutions for data-driven Global 2000 companies in the pharmaceutical industry.
Automation > IT & Software > News
Merck introduces new gene editing technology to modify CHO cell lines
Merck has introduced a gene editing technology that can modify CHO cell lines to be resistant to minute virus of mice (MVM), a common contamination threat that remains despite the shift to chemically defined, animal component-free manufacturing processes.
Automation > IT & Software > News
Compugen enhances LINKS computational platform
Compugen disclosed that its LINKS computational platform, initially designed for the characterization and differentiation of existing novel drug target candidates, has been enhanced to include the in silico discovery of new immuno-oncology drug targets, with a specific focus on the discovery of myeloid targets within the tumor microenvironment (TME).
Automation > IT & Software > News
Daiichi Sankyo chooses Veeva Vault to streamline submissions, eTMF, and quality management
Daiichi Sankyo has selected Veeva Systems' Veeva Vault eTMF, Veeva Vault QualityDocs, and Veeva Vault Submissions to unify content management throughout its research and development (R&D) operations worldwide.
Automation > IT & Software > News
Eleven Biotherapeutics completes exclusive licensing deal for IL-6 antagonist antibody technology
Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced the effectiveness of the exclusive licensing deal with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche).
Automation > IT & Software > News
Genmab signs commercial license deal with Gilead for DuoBody technology
Genmab has entered an agreement to grant Gilead Sciences an exclusive license and an option on a second exclusive license, to use the DuoBody technology platform to create and develop bispecific antibody candidates for a therapeutic program targeting HIV.
Automation > IT & Software > News
Lantern Pharma signs deal to evaluate BioNumerik’s Tavocept
Lantern Pharma has entered into an exclusive agreement to evaluate BioNumerik Pharmaceuticals' Tavocept for human therapeutic indications using Lantern’s 5-M theranostic platform.
Automation > IT & Software > News
Clinical stage biotechnology firm Ambrx closes $45m round of financing
Ambrx, a clinical stage biotechnology company that discovers and develops first-in-class and best-in-class optimized protein therapeutics known as bio-conjugates, has closed a $45m round of financing led by Apricot Capital and Northeast Securities Prosperity Healthcare Fund.
Automation > IT & Software > News
Pluristem Therapeutics adopts Medidata's cloud technology platform
Placenta-based cell therapy products developer Pluristem Therapeutics has adopted Medidata's cloud technology platform.
Automation > IT & Software > News
Ligand signs multi-program LTP technology licensing deal with Nucorion Pharmaceuticals
Ligand Pharmaceuticals has signed a license agreement for three programs utilizing Ligand’s LTP (Liver Targeting Prodrug) technology with Nucorion Pharmaceuticals, a venture-funded biotechnology company focused on developing anti-cancer and anti-viral agents initially directed to China.
Automation > IT & Software > News
Synaffix achieves improved therapeutic index compared to both FDA-approved ADCs
Synaffix has completed a new set of preclinical studies that further supports the potential for its technology to enable safer and more effective targeted cancer therapeutics.
Automation > IT & Software > News
31-45 of 1781 results